Fig. 2: Antitumor activity of T-αFGL2 in vivo. | Nature Communications

Fig. 2: Antitumor activity of T-αFGL2 in vivo.

From: FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells

Fig. 2

a Representative micrographs of FGL2 expression in the brains of mice with glioma. Slides stained with mouse IgG were used as negative controls. Images are representative of results from three samples with multiple fields of view for each sample. b Schematic of the orthotopic DBT glioma model. On days 3–5 after DBT tumor cell inoculation, mice were treated with temozolomide (TMZ), followed by infusion of T-Ctr or T-αFGL2 cells on days 6 and 13. c Representative bioluminescence images of DBT-luc tumor growth in the orthotopic glioma model shown in (b). d Flux vs. time [p/s] data (mean ± SEM) for the orthotopic glioma model shown in (b) (n = 5 mice). e Kaplan–Meier survival curves of mice shown in (b) (n = 10 mice for NT group, n = 13 for T-Ctr group, n = 20 for T-αFGL2 group), log-rank test. The experiments were repeated three times with similar results. f Representative H&E staining of brains in (b) collected on day 14 after tumor cell inoculation. Images are representative of results from three samples with multiple fields of view for each sample. Data are representative of three mice. g Schematic of the orthotopic GL261 glioma model. h Kaplan–Meier survival curves of mice in (g) (n = 6 for T-Ctr group, n = 7 for T-αFGL2 group), log-rank test. The experiments were repeated twice with similar results.

Back to article page